Silvia Vega-Rubín-de-Celis

Silvia Vega-Rubín-de-Celis


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2021 in iScience
Verified
Journal Article
Open access
Adam KrysztofiakAdam Krysztofiak
Adam Krysztofiak
KSKlaudia Szymonowicz
Klaudia Szymonowicz
JHJulian Hlouschek
Julian Hlouschek
KXKexu Xiang
Kexu Xiang
CWChristoph Waterkamp
Christoph Waterkamp
Johann MatschkeJohann Matschke
Johann Matschke
Cancer bioenergetics fuel processes necessary to maintain viability and growth under stress conditions. We hypothesized that cancer metabolism supports the repair of radiation-induced DNA double-stranded breaks (DSBs). We combined the systematic collection of metabolic and radiobiological data from a panel of irradiated cancer cell lines with mathematical modeling and identified a common metabolic response with impact on the DSB repair kinetics, including a mitochondrial shutdown followed by compensatory glycolysis and resumption of mitochondrial function. Combining ionizing radiation (IR) with inhibitors of the compensatory glycolysis or mitochondrial respiratory chain slowed mitochondrial recovery and DNA repair kinetics, offering an opportunity for therapeutic intervention. Mathematical modeling allowed us to generate new hypotheses on general and individual mechanisms of the radiation response with relevance to DNA repair and on metabolic vulnerabilities induced by cancer radiotherapy. These discoveries will guide future mechanistic studies for the discovery of metabolic targets for overcoming intrinsic or therapy-induced radioresistance.

24 December 2020 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
DMDevina Mitra
Devina Mitra
SVSilvia Vega-Rubín-de-Celis
Silvia Vega-Rubín-de-Celis
NRNadine Royla
Nadine Royla
SBStephan Bernhardt
Stephan Bernhardt
HWHeike Wilhelm
Heike Wilhelm
SWStefan Wiemann
Stefan Wiemann
Uncontrolled proliferation and altered metabolic reprogramming are hallmarks of cancer. Active glycolysis and glutaminolysis are characteristic features of these hallmarks and required for tumorigenesis. A fine balance between cancer metabolism and autophagy is a prerequisite of homeostasis within cancer cells. Here we show that glutamate pyruvate transaminase 2 (GPT2), which serves as a pivot between glycolysis and glutaminolysis, is highly upregulated in aggressive breast cancers, particularly the triple‐negative breast cancer subtype. Abrogation of this enzyme results in decreased tricarboxylic acid cycle intermediates, which promotes the rewiring of glucose carbon atoms and alterations in nutrient levels. Concordantly, loss of GPT2 results in an impairment of mechanistic target of rapamycin complex 1 activity as well as the induction of autophagy. Furthermore, in vivo xenograft studies have shown that autophagy induction correlates with decreased tumor growth and that markers of induced autophagy correlate with low GPT2 levels in patient samples. Taken together, these findings indicate that cancer cells have a close network between metabolic and nutrient sensing pathways necessary to sustain tumorigenesis and that aminotransferase reactions play an important role in maintaining this balance.

1 March 2021 in iScience
Verified
Journal Article
Open access
JNJennifer Niersch
Jennifer Niersch
SVSilvia Vega-Rubín-de-Celis
Silvia Vega-Rubín-de-Celis
ABAnna Bazarna
Anna Bazarna
SMSvenja Mergener
Svenja Mergener
VJVerena Jendrossek
Verena Jendrossek
Samuel Peña-LlopisSamuel Peña-Llopis
Samuel Peña-Llopis
Synonymous mutations are generally disregarded by genomic analyses because they are considered non-pathogenic. We identified and characterized a somatic synonymous mutation in the epigenetic modifier and tumor suppressor BAP1, resulting in exon skipping and complete protein inactivation. This radically altered the prognosis of a clear-cell renal cell carcinoma patient from The Cancer Genome Atlas (TCGA) with a PBRM1 mutation (a predictor biomarker for positive responses to immune checkpoint inhibitors) from good (an estimated overall survival of 117 months) to a very bad prognosis (an estimated overall survival of 31 months), emphasizing the importance of scrutinizing synonymous mutations near acceptor splice sites of cancer genes for accurate precision medicine.

5 January 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JMJetsy Montero-Vergara
Jetsy Montero-Vergara
KPKira Plachetta
Kira Plachetta
LKLisa Kinch
Lisa Kinch
SBStephan Bernhardt
Stephan Bernhardt
KKKriti Kashyap
Kriti Kashyap
SVSilvia Vega-Rubín-de-Celis
Silvia Vega-Rubín-de-Celis
GRB2 is an adaptor protein of HER2 (and several other tyrosine kinases), which we identified as a novel BECN1 (Beclin 1) interacting partner. GRB2 co-immunoprecipitated with BECN1 in several breast cancer cell lines and regulates autophagy through a mechanism involving the modulation of the class III PI3Kinase VPS34 activity. In ovo studies in a CAM (Chicken Chorioallantoic Membrane) model indicated that GRB2 knockdown, as well as overexpression of GRB2 loss-of-function mutants (Y52A and S86A-R88A) compromised tumor growth. These differences in tumor growth correlated with differential autophagy activity, indicating that autophagy effects might be related to the effects on tumorigenesis. Our data highlight a novel function of GRB2 as a BECN1 binding protein and a regulator of autophagy.

3 August 2025 in Autophagy
Verified
Journal Article
Open access
SVSilvia Vega-Rubín-de-Celis
Silvia Vega-Rubín-de-Celis
AKAmanda Kristani
Amanda Kristani
MKMatthias Kudla
Matthias Kudla
SMSvenja Mergener
Svenja Mergener
ACAndrés Corrochano-Ruiz
Andrés Corrochano-Ruiz
Samuel Peña-LlopisSamuel Peña-Llopis
Samuel Peña-Llopis
BAP1 is a tumor suppressor and epigenetic modifier that is frequently mutated in cancer, leading to increased aggressiveness and metastasis, as well as poor patient survival. Unfortunately, there are currently no specific therapies for metastatic tumors harboring BAP1 mutations. In this study, we have identified a new targetable BAP1-associated autophagic vulnerability. We demonstrate that BAP1 transcriptionally regulates the proto-oncogene SRC, a non-receptor tyrosine kinase. SRC then binds to, phosphorylates, and inactivates BECN1 (Beclin 1), an essential autophagy protein. This inhibits autophagy in cells derived from various cancer types with BAP1 mutations. Treatment of these cells with SRC inhibitors (such as dasatinib, bosutinib and saracatinib) and autophagy-inducing drugs (such as Tat-BECN1, SW076956 and SW063058) demonstrated a synergistic interaction between these compounds both in vitro and in ovo using a chick Chorioallantoic Membrane (CAM) assay. Furthermore, ex vivo studies employing patient-derived tumor organoids (PDTOs) of uveal melanoma (UM) and clear-cell renal cell carcinoma (ccRCC) as preclinical models have substantiated the synergism of these drugs, preferentially in the context of BAP1 loss. Our findings elucidate a novel BAP1-SRC-BECN1-autophagy regulatory axis that can be exploited therapeutically in precision oncology through the combination of SRC inhibitors and autophagy inducers, contingent upon patient stratification for BAP1 loss.Significance: Deadly cancers with BAP1 mutations suppress autophagy by phosphorylating the autophagy regulator BECN1 via the proto-oncogene SRC. Treatment with SRC inhibitors and autophagy inducers exhibited synergism in vitro, in ovo and in patient-derived tumor organoids with BAP1 loss, paving the way for treating BAP1-deficient cancers with autophagy inducers and kinase inhibitors.

1 January 2022
Verified
Book Chapter
Open access
PDF file
RWRainer Will
Rainer Will
KBKatja Bauer
Katja Bauer
MKMatthias Kudla
Matthias Kudla
JMJetsy Montero-Vergara
Jetsy Montero-Vergara
SWStefan Wiemann
Stefan Wiemann
SVSilvia Vega-Rubín-de-Celis
Silvia Vega-Rubín-de-Celis
Autophagy is an intracellular degradation process that maintains the cellular homeostasis and it is regulated in multiple ways, both in health and disease. Assessment of autophagic flux in cells is an important approach for understanding the function of autophagy in biological contexts. Here, we describe a new tool for the qualitative and quantitative determination of autophagic flux using a dual lentiviral reporter system that generates a fusion HiBiT-GFP-LC3B protein suitable for generating stable cell lines.